Related Experiment Videos
Teniposide (VM-26) in brain tumors
1Scientific Department, Cancer Research Campaign, London, England.
Seminars in Oncology
|April 1, 1992
Summary
Teniposide shows promise for treating brain tumors, particularly small cell lung cancer with brain metastasis, due to preferential uptake in tumor tissue. Further controlled trials are needed to optimize its use in adult glioma treatment.
Area of Science:
- Neuro-oncology
- Medical oncology
- Pharmacology
Background:
- Teniposide's activity in glioma was noted in 1971.
- Recent investigations focus on its efficacy in small cell lung cancer and brain metastases.
- Preferential uptake of teniposide in brain tumor tissue has been observed.
Purpose of the Study:
- To systematically investigate the effectiveness of teniposide in small cell lung cancer and associated brain metastases.
- To evaluate the single-agent activity and combination therapy of teniposide in adult glioma.
- To highlight the need for controlled trials to optimize teniposide's clinical application.
Main Methods:
- Review of existing literature on teniposide's use in glioma and brain metastases.
- Analysis of studies reporting single-agent activity in astrocytomas.
- Examination of combination therapy trials, particularly with nitrosoureas, doxorubicin, and lomustine.
Main Results:
- Teniposide demonstrates effectiveness in small cell lung cancer and brain metastases.
- Single-agent activity in astrocytomas is reported, but data interpretation is challenging due to study variations.
- Combination therapy results are difficult to evaluate consistently due to differing response definitions.
Conclusions:
- Teniposide shows significant potential for treating adult glioma.
- Variations in study designs and response definitions hinder definitive evaluation of teniposide's efficacy.
- Controlled clinical trials are essential to confirm and optimize teniposide's role in glioma treatment.